A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 13 Dec 2016 Results published in the Journal of Pediatrics.
- 04 Apr 2016 Results presented at The 98th Annual Meeting of the Endocrine Society.
- 28 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.